645 related articles for article (PubMed ID: 28343126)
21. PI3K/Akt promotes feedforward mTORC2 activation through IKKα.
Dan HC; Antonia RJ; Baldwin AS
Oncotarget; 2016 Apr; 7(16):21064-75. PubMed ID: 27027448
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol (3,4) bisphosphate-specific phosphatases and effector proteins: A distinct branch of PI3K signaling.
Li H; Marshall AJ
Cell Signal; 2015 Sep; 27(9):1789-98. PubMed ID: 26022180
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
24. Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
Yang Q; Jiang W; Hou P
Semin Cancer Biol; 2019 Dec; 59():112-124. PubMed ID: 30951826
[TBL] [Abstract][Full Text] [Related]
25. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis.
Hao NB; Tang B; Wang GZ; Xie R; Hu CJ; Wang SM; Wu YY; Liu E; Xie X; Yang SM
Cancer Lett; 2015 May; 361(1):57-66. PubMed ID: 25727320
[TBL] [Abstract][Full Text] [Related]
26. PI3K and AKT: Unfaithful Partners in Cancer.
Faes S; Dormond O
Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
[TBL] [Abstract][Full Text] [Related]
27. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
28. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review).
Shi X; Wang J; Lei Y; Cong C; Tan D; Zhou X
Mol Med Rep; 2019 Jun; 19(6):4529-4535. PubMed ID: 30942405
[TBL] [Abstract][Full Text] [Related]
29. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review).
Zhao HF; Wang J; Tony To SS
Int J Oncol; 2015 Aug; 47(2):429-36. PubMed ID: 26082006
[TBL] [Abstract][Full Text] [Related]
30. PI3K/AKT signaling pathway and cancer: an updated review.
Martini M; De Santis MC; Braccini L; Gulluni F; Hirsch E
Ann Med; 2014 Sep; 46(6):372-83. PubMed ID: 24897931
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
32. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between Phosphoinositide 3-kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer.
Karimian A; Mir SM; Parsian H; Refieyan S; Mirza-Aghazadeh-Attari M; Yousefi B; Majidinia M
J Cell Biochem; 2019 Jun; 120(6):10248-10272. PubMed ID: 30592328
[TBL] [Abstract][Full Text] [Related]
34. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
35. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.
Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A
Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634
[TBL] [Abstract][Full Text] [Related]
37. Apigenin inhibits cell proliferation, migration, and invasion by targeting Akt in the A549 human lung cancer cell line.
Zhou Z; Tang M; Liu Y; Zhang Z; Lu R; Lu J
Anticancer Drugs; 2017 Apr; 28(4):446-456. PubMed ID: 28125432
[TBL] [Abstract][Full Text] [Related]
38. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
39. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression.
Cohen-Solal KA; Boregowda RK; Lasfar A
Mol Cancer; 2015 Jul; 14():137. PubMed ID: 26204939
[TBL] [Abstract][Full Text] [Related]
40. Chemotactic activation of Dictyostelium AGC-family kinases AKT and PKBR1 requires separate but coordinated functions of PDK1 and TORC2.
Liao XH; Buggey J; Kimmel AR
J Cell Sci; 2010 Mar; 123(Pt 6):983-92. PubMed ID: 20200230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
